# Trade Mark Journal No.2026/003 16 January 2026

## WO0000001894108 (5,42)

Office of origin: France

Date of International Registration:5 November 2025
Date of designation in the UK: 5 November 2025

International priority date claimed: 6 May 2025 (France) (5145173)

Class 5
  Allogeneic or autologous cellular and molecular innovative therapy medications; pharmaceutical products for treating oncological diseases; pharmaceutical products for treating diseases of the immune system; pharmaceutical products for treating inflammatory diseases; pharmaceutical products for treating autoimmune diseases; immunomodulatory medicines; anti-inflammatory medicines; cellular-function activating agents for medical purposes; biological preparations for cancer treatment; biological preparations for medical use; biochemical preparations for medical use; biological tissue cultures for medical use; stem cells for use in cell and gene therapies; cell culture media for medical use.
Class 42
  Research and development services for innovative solutions for allogeneic and autologous molecular and cellular therapy; design services for innovative solutions for allogeneic or autologous molecular and cellular therapy; medical and pharmacological research services; research and development in the field of stem cells, cell and gene therapy and biotechnology; providing scientific research information in the field of stem cells, cell and gene therapy and biotechnology; clinical trials; providing information concerning clinical trial results for pharmaceutical products in the field of autologous or allogeneic cellular and molecular therapy; technical project study services in the field of allogeneic or autologous cellular and molecular therapy; provision of information and data with respect to medical research and development.

THERALLO

Representative: BEACCO Marine ICOSA, 83 Avenue Denfert-Rochereau, F-75014 PARIS, FRANCE